Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression >= 50% and Their Relationship With Clinical Outcomes

A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, F Cappuzzo, Joachim Aerts, R Giusti, E Bria, D Cortinovis, F Grossi, MR Migliorino, D Galetta, F Passiglia, R Berardi, F Mazzoni, V Di Noia, D Signorelli, A Tuzi, A GelibterP Marchetti, M Macerelli, F Rastelli, R Chiari, D De Rocco, A Inno, P Di Marino, G Mansueto, F Zoratto, M Santoni, M Tudini, M Ghidini, M Filetti, A Catino, P Pizzutilo, L Sala, MA Occhipinti, F Citarella, R Marco, M Torniai, Luca Cantini, A Follador, V Sforza, O Nigro, MG Ferrara, E D'Argento, A Leonetti, L Pettoruti, L Antonuzzo, S Scodes, L Landi, G Guaitoli, C Baldessari, F Bertolini, L Della Gravara, MG Dal Bello, Bob Belderbos, M De Filippis, C Cecchi, S Ricciardi, C Donisi, A De Toma, C Proto, A Addeo, O Cantale, B Ricciuti, C Genova, A Morabito, D Santini, C Ficorella, K Cannita

Research output: Contribution to journalArticleAcademic

53 Citations (Scopus)
Original languageEnglish
Pages (from-to)498-508.e2
JournalClinical Lung Cancer
Volume21
Issue number6
DOIs
Publication statusPublished - 2020

Research programs

  • EMC MM-04-42-02

Cite this